Bimetallic nanoparticles showed an IC50 of 65 µg/mL against HeLa cells, suggesting therapeutic potential in nanomedicine.
Nowadays, the development of innovative and affordable nanomedicine with improved antimicrobial and anticancer therapeutic potential is in demand for improved disease management and better recovery rates. In this study, we present Cu2+@CuSeO3 nanoparticles prepared using rapid green synthetic preparation, followed by characterization of the nanoparticles using different analytical and spectroscopic methods like TEM, XPS, FTIR and PXRD. Bimetallic nanoparticles Cu2+@CuSeO3 showed a maximum zone of inhibition of 16.71 ± 0.35 mm against S. aureus and 12.50 ± 0.91 against P. Aeruginosa, much higher efficacy as compared to the monometallic nanoparticles, CuNP and SeNP. This result suggests that bimetallic composite Cu2+@CuSeO3 can be used as a potential nanomedicine, as they showed antimicrobial properties of similar activity as tetracyclines. Additionally, Cu2+@CuSeO3 nanoparticles were also found to have antiproliferative properties against HeLa cells with an IC50 value of 65 µg/mL, which is much lower than the IC50 values of the reported bimetallic nanocomposites made of combined Cu and Se, establishing their anticancer therapeutic potential. This study proves that Cu2+@CuSeO3 nanoparticles with dual functionalities are found to exert enhanced effect towards antimicrobial and anticancer activities as compared to mononuclear nanoparticles like CuNP and SeNP.
No takes yet. Share an insight, caveat, or question.
Das et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: